目的 系統(tǒng)評價索利那新聯(lián)合坦索羅辛治療Ⅲ型前列腺炎的臨床療效。方法 計算機檢索PubMed、EMbase、Cochrane Library、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、中國期刊全文數(shù)據(jù)庫（CNKI）、中文科技期刊全文數(shù)據(jù)庫（VIP）和萬方數(shù)據(jù)庫，收集索利那新聯(lián)合坦索羅辛治療Ⅲ型前列腺炎的隨機對照試驗（RCT），檢索時限2000年1月-2017年6月。采用Cochrane協(xié)作網(wǎng)推薦的RevMan 5.3軟件對各效應指標進行Meta分析。結果 共納入9項RCTs，計938例Ⅲ型前列腺炎患者。Meta分析結果顯示，聯(lián)合用藥組痊愈率[OR=1.82，95%CI（1.30，2.56），P=0.000 5]與總有效率[OR=4.46，95%CI（2.86，6.95），P < 0.001]均顯著高于對照組，差異有統(tǒng)計學意義（P < 0.05）；聯(lián)合用藥組NIH-CPSI評分、疼痛癥狀評分、排尿癥狀評分、生活質量評分均顯著低于對照組，差異有統(tǒng)計學意義（P < 0.05）。結論 索利那新聯(lián)合坦索羅辛治療Ⅲ型前列腺炎較單用坦索羅辛的臨床效果好。受納入文獻的質量和樣本量限制，上述結論尚待更多大樣本、高質量的研究予以進一步證實。

Objective To evaluate the efficacy of solifenacin combined with tamsulosin in the treatment of type III prostatitis. Methods The randomized controlled trials (RCT) of solifenacin combined with tamsulosin in the treatment of type III prostatitis were searched from PubMed, EMbase, Cochrane Library, CBM, CNKI, VIP database, and Wangfang detabase. Data were collected from January 2000 to June 2017 and also retrieved manually. At the same time, Meta analysis was carried out by using RevMan 5.3 software. Results A total of nine RCTs were included, including 938 patients with type III prostatitis. Meta analysis results showed that the cure rate[OR=1.82, 95%CI (1.30, 2.56), P=0.000 5] and effective rate[OR=4.46, 95%CI (2.86, 6.95), P < 0.001] of treatment group were significantly higher than those in control group. Moreover, NIH-CPSI score, symptom of pain score, voiding symptom score and life quality score of treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Solifenacin combined with tamsulosin in the treatment of type III prostatitis has better effect than tamsulosin monotherapy. However, there is limit of methodological quality and sample size, so more RCTs with high quality, large sample, and long-term follow up are required for further verification.